Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $2.05 million for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
Taysha Gene Therapies Price Performance
TSHA traded down $0.03 during trading on Friday, reaching $1.61. 1,637,698 shares of the company traded hands, compared to its average volume of 2,133,073. The company has a market cap of $329.95 million, a P/E ratio of 2.56 and a beta of 0.92. The firm has a fifty day simple moving average of $1.71 and a 200 day simple moving average of $2.00. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32.
Analysts Set New Price Targets
TSHA has been the subject of several analyst reports. Chardan Capital reissued a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Canaccord Genuity Group increased their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Monday, January 6th. JMP Securities restated a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $6.63.
View Our Latest Stock Report on Taysha Gene Therapies
About Taysha Gene Therapies
(
Get Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
